Ifosfamide in testicular cancer.

Abstract

Ifosfamide has demonstrated significant activity as salvage therapy in patients with testicular tumors refractory to cisplatin-containing induction chemotherapy regimens. Used as a single agent, ifosfamide produces objective responses in approximately 1 of 5 heavily pretreated patients failing to respond to any other agents. When ifosfamide is administered in combination with cisplatin and other agents, approximately 40% to 50% of pretreated patients with recurrent germ cell tumors achieve a complete remission. Studies currently under way should determine the optimal use of ifosfamide against testicular neoplasms, including its possible role as part of initial induction therapy.

• Authors: P J Loehrer Sr
• Journal: Seminars in oncology (Semin Oncol) Vol. 17 Issue 2 Suppl 4 Pg. 2-5 (Apr 1990) ISSN: 0093-7754 [Print] United States
• PMID: 2159186 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)

Chemical References

• Vinblastine
• Etoposide
• Cisplatin
• Ifosfamide

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cisplatin (administration & dosage)
• Drug Synergism
• Etoposide (administration & dosage)
• Humans
• Ifosfamide (administration & dosage)
• Male
• Neoplasms, Germ Cell and Embryonal (drug therapy)
• Testicular Neoplasms (drug therapy)
• Vinblastine (administration & dosage)